Trial reportClinical, cosmetic and investigational dermatology2025
Safety and Clinical Efficacy of Kūlaris
Trial report in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: There is a growing interest in nutraceutical supplements for ameliorating skin disorders owing to their multifaceted role and tolerability. In this study, we investigated the safety and efficacy of a unique herbal formulation (Kūlaris Patients and Methods: In a randomized, placebo-controlled, parallel-group study design, 100 male and female subjects (18-40 years) with mild to severe acne were allocated (1:1 ratio) to receive 450 mg capsules of either Kūlaris or placebo once daily for 12 weeks. Results: Kūlaris treatment markedly reduced acne severity, with the majority of subjects achieving success in the Investigator Global Assessment (IGA) score (odds ratio = 7.88, Conclusion: This study provides compelling evidence to support the potential use of Kūlaris as a therapeutic supplement or an adjunctive therapy to treatment of acne vulgaris.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.